Barcelona Alzheimer Treatment & Research Center

Archive for the totes les publicacions científiques Category

El tratamiento longitudinal de la enfermedad de Alzheimer. Del envejecimiento a la enfermedad de Alzheimer.

El tratamiento longitudinal de la enfermedad de Alzheimer. Del envejecimiento a la enfermedad de Alzheimer. Boada, M., Tárraga, L. (1999). Continua Neurológica, vol 1 (1): 82-106.

Evaluation of Candidate Genes Related to Neuronal Apoptosis in Late-Onset Alzheimer’s Disease.

Evaluation of Candidate Genes Related to Neuronal Apoptosis in Late-Onset Alzheimer’s Disease. Moreno-Grau S, Barneda B, Carriba P, Marín J, Sotolongo-Grau O, Hernández I, Rosende-Roca M, Mauleón A,Vargas L, Espinosa A, Alegret M, Rodriguez O, Ortega G, Fernández MV, López-Arrieta J, Tárraga L, Boada M, Antúnez C, López J, Ruiz A, Comella JX. J Alzheimers Dis. 2015 Jan 22. [Epub ahead of print]

Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold?

Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? Palasí A, Gutiérrez-Iglesias B, Alegret M, Pujadas F, Olabarrieta M, Liébana D, Quintana M, Álvarez-Sabín J, Boada M. J Neurol. 2015 Mar 21. [Epub ahead of print]

PLD3 in non-familial Alzheimer’s Disease.

PLD3 in non-familial Alzheimer’s Disease. Ramirez A, Heilmann S, Drichel D, Clarimon J, Fernández V, Lacour A, Wagner H, Thelen M, Hernández I, Fortea J, Alegret M, Blesa R, Mauleón A, Rosende Roca M, Kornhuber J, Peters O, Heun R, Frölich L, Hüll M, Heneka M, Rüther E, Riedel-Heller S, Scherer M, Wiltfang

Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study.

Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Cuyvers E, van der Zee J, Bettens K, Engelborghs S, Vandenbulcke M, Robberecht C, Dillen L, Merlin C, Geerts N, Graff C, Thonberg H, Chiang HH, Pastor P, Ortega-Cubero S, Pastor

Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain.

Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Dols-Icardo, O , Nebot I , Gorostidi A, Ortega-Cubero S , Hernández I, Rojas-García R, García-Redondo A, Povedano M, Lladó A, Álvarez V, Sánchez-Juan P, Pardo J , Jericó I, Vázquez-Costa J, Sevilla

Convergent genetic and expression data implicate immunity in Alzheimer’s disease.

Convergent genetic and expression data implicate immunity in Alzheimer’s disease. International Genomics of Alzheimer’s Disease Consortium (IGAP); International Genomics of Alzheimer’s Disease Consortium IGAP. Alzheimers Dement. 2014 Dec 20. [Epub ahead of print]

Diagostic accuracy of FTD behavioural frontotemporal dementia criteria in a clinicopathological cohort.

Diagostic accuracy of FTD behavioural frontotemporal dementia criteria in a clinicopathological cohort. Balasa M, Gelpi E, Martín I, Antonell A, Rey M, Grau-Rivera O, Molinuevo J, Sánchez-Valle R, Lladó A; Catalan collaborative Study Group for FTLD. Neuropathol Appl Neurobiol. 2014 Nov 10. [Epub ahead of print]

Association of TMEM106B rs1990622 Marker and Frontotemporal Dementia: Evidence for a Recessive Effect and Meta-Analysis.

Association of TMEM106B rs1990622 Marker and Frontotemporal Dementia: Evidence for a Recessive Effect and Meta-Analysis. Hernández I, Rosende-Roca M, Alegret M, Mauleón A, Espinosa A, Vargas L,Sotolongo-Grau O, Tárraga L, Boada M, Ruiz A. J Alzheimers Dis. 2014 Aug 5. [Epub ahead of print] PDF

Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.

Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. Boada M, Ramos-Fernández E, Guivernau B, Muñoz FJ, Costa M, Ortiz AM, Jorquera JI, Núñez L, Torres M,

Página 1 de 41234